Longer-acting Botox maker says demand is seeing a spike
New York
PATIENTS are already clamouring for "the longer-acting Botox", a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News.
The launch won't happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer-acting product for therapeutic goals.
RT002, as the drug is known, is still in late-stage testing for its first indication - expected to be glabellar lines - for which results are not expected until the second half of this year, with a possible product launch in 2020.
"People underestimate the power of this data," Mr Browne said, expecting it to be a "major de-risking event" for Revance when results from the study, known as "Sakura", are read out later this year.
Revance is targeting an FDA label to show the RT002, a botulinum toxin similar to Allergan's Botox, lasts up to six months, compared to a three- to four-month label claim for Allergan's best-selling product.
The company says it has data that proves the six-month duration claim, said chief operating officer Abhay Joshi, a former 18-year veteran with Allergan. Revance sees this as a "performance product" and will seek "premium pricing", Mr Browne said. He plans to look at annual costs of RT002 over the cost of a single treatment. The company also announced at its investor day that it would target developing RT002 for migraines. BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself